seed
Stage
2020
Founded
1
Investors
About
Allergios develops an AI-powered microfluidic platform for functional allergy diagnostics, aiming to replace risky and resource-intensive oral provocation tests with a cell-based blood test that analyzes individual immune responses to allergens.
Explore Allergios's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.